CoChat

Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade

Published version of a preprint

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

Abstract

The antiapoptotic protein BCL2 plays critical roles in regulating lymphocyte development and immune responses, and has also been implicated in tumorigenesis and tumor survival. However, it is unknown whether BCL2 is critical for antitumor immune responses. We evaluated whether venetoclax, a selective small-molecule inhibitor of BCL2, would influence the antitumor activity of immune checkpoint inhibitors (ICI). We demonstrate in mouse syngeneic tumor models that venetoclax can augment the antitumor efficacy of ICIs accompanied by the increase of PD-1+ T effector memory cells. Venetoclax did not impair human T-cell function in response to antigen stimuli in vitro and did not antagonize T-cell activation induced by anti–PD-1. Furthermore, we demonstrate that the antiapoptotic family member BCL-XL provides a survival advantage in effector T cells following inhibition of BCL2. Taken together, these data provide evidence that venetoclax should be further explored in combination with ICIs for cancer therapy. Significance: The antiapoptotic oncoprotein BCL2 plays critical roles in tumorigenesis, tumor survival, lymphocyte development, and immune system regulation. Here we demonstrate that venetoclax, the first FDA/European Medicines Agency–approved BCL2 inhibitor, unexpectedly can be combined preclinically with immune checkpoint inhibitors to enhance anticancer immunotherapy, warranting clinical evaluation of these combinations. This article is highlighted in the In This Issue feature, p. 1

Overview

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-19-0759

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

See all 126

Metadata

Authors
Kohlhapp, F. J., Haribhai, D., Mathew, R., Duggan, R., Ellis, P. A., Wang, R., Lasater, E. A., Shi, Y., Dave, N., Riehm, J. J., Robinson, V. A., Do, A. D., Li, Y., Orr, C. J., Sampath, D., Raval, A., Merchant, M., Bhathena, A., Salem, A. H., Hamel, K. M., Leverson, J. D., Donawho, C., Pappano, W. N., & Uziel, T.
Affiliations
  • AbbVie (United States) (US)
  • Genentech (US)
  • 5Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Ain Shams University (EG)
Corresponding author
  • Pappano, William N.
  • Uziel, Tamar
Venue
Cancer Discovery
Published
2021-01-01
Volume
11
Issue
1
Pages
68-79
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3083749790
Cited by
126
References
26
Citations by year
2026: 10 · 2025: 21 · 2024: 31 · 2023: 25 · 2022: 23 · 2021: 14
FWCI
5.78
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • AbbVie
  • Genentech
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
venetoclax, BCL-2 inhibition, immune checkpoint blockade, PD-1, effector T cells, Bcl-xL, antitumor immunity, combination cancer therapy, apoptosis, T cell memory
MeSH terms
Immune Checkpoint Inhibitors, Sulfonamides, T-Lymphocytes, Bridged Bicyclo Compounds, Heterocyclic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade. https://app.cochat.ai/papers/10.1158/2159-8290.cd-19-0759
The paper
Kohlhapp, F. J., Haribhai, D., Mathew, R., Duggan, R., Ellis, P. A., Wang, R., Lasater, E. A., Shi, Y., Dave, N., Riehm, J. J., Robinson, V. A., Do, A. D., Li, Y., Orr, C. J., Sampath, D., Raval, A., Merchant, M., Bhathena, A., Salem, A. H., . . . Uziel, T. (2021). Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-19-0759

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.